These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27531419)

  • 1. Development of a screening method for co-amorphous formulations of drugs and amino acids.
    Kasten G; Grohganz H; Rades T; Löbmann K
    Eur J Pharm Sci; 2016 Dec; 95():28-35. PubMed ID: 27531419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-former selection for co-amorphous drug-amino acid formulations.
    Kasten G; Löbmann K; Grohganz H; Rades T
    Int J Pharm; 2019 Feb; 557():366-373. PubMed ID: 30578980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of preparation technique on co-amorphization of carvedilol with acidic amino acids.
    Mishra J; Löbmann K; Grohganz H; Rades T
    Int J Pharm; 2018 Dec; 552(1-2):407-413. PubMed ID: 30278256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptides as co-formers in co-amorphous systems.
    Wu W; Löbmann K; Schnitzkewitz J; Knuhtsen A; Pedersen DS; Rades T; Grohganz H
    Eur J Pharm Biopharm; 2019 Jan; 134():68-76. PubMed ID: 30468836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions.
    Löbmann K; Laitinen R; Strachan C; Rades T; Grohganz H
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):882-8. PubMed ID: 23567485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
    Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
    Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability.
    Laitinen R; Löbmann K; Grohganz H; Strachan C; Rades T
    Mol Pharm; 2014 Jul; 11(7):2381-9. PubMed ID: 24852326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of molecular descriptors in the development of co-amorphous formulations.
    Meng-Lund H; Kasten G; Jensen KT; Poso A; Pantsar T; Rades T; Rantanen J; Grohganz H
    Eur J Pharm Sci; 2018 Jul; 119():31-38. PubMed ID: 29649569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential application of low molecular weight excipients for amorphization and dissolution enhancement of carvedilol.
    Pešić N; Dapčević A; Ivković B; Kachrimanis K; Mitrić M; Ibrić S; Medarević D
    Int J Pharm; 2021 Oct; 608():121033. PubMed ID: 34419592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers.
    Wu W; Grohganz H; Rades T; Löbmann K
    Eur J Pharm Sci; 2021 Jan; 156():105582. PubMed ID: 33039568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization.
    Ruponen M; Visti M; Ojarinta R; Laitinen R
    Eur J Pharm Biopharm; 2018 Aug; 129():247-256. PubMed ID: 29894814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation Mechanism of Coamorphous Drug-Amino Acid Mixtures.
    Jensen KT; Larsen FH; Cornett C; Löbmann K; Grohganz H; Rades T
    Mol Pharm; 2015 Jul; 12(7):2484-92. PubMed ID: 26057950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing mechanical activation-induced amorphisation of salbutamol sulphate by co-processing with selected carboxylic acids.
    Curtin V; Amharar Y; Gallagher KH; Corcoran S; Tajber L; Corrigan OI; Healy AM
    Int J Pharm; 2013 Nov; 456(2):508-16. PubMed ID: 23994365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of excipients in comilling on mitigating milling-induced amorphization or structural disorder of crystalline pharmaceutical actives.
    Balani PN; Ng WK; Tan RB; Chan SY
    J Pharm Sci; 2010 May; 99(5):2462-74. PubMed ID: 19902526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and characterization of amorphous ciprofloxacin-amino acid salts.
    Mesallati H; Conroy D; Hudson S; Tajber L
    Eur J Pharm Biopharm; 2017 Dec; 121():73-89. PubMed ID: 28919470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspartame as a co-former in co-amorphous systems.
    Wu W; Löbmann K; Schnitzkewitz J; Knuhtsen A; Pedersen DS; Grohganz H; Rades T
    Int J Pharm; 2018 Oct; 549(1-2):380-387. PubMed ID: 30075253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sinapic Acid Co-Amorphous Systems with Amino Acids for Improved Solubility and Antioxidant Activity.
    Garbiec E; Rosiak N; Tykarska E; Zalewski P; Cielecka-Piontek J
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-Amorphous Formation of High-Dose Zwitterionic Compounds with Amino Acids To Improve Solubility and Enable Parenteral Delivery.
    Zhu S; Gao H; Babu S; Garad S
    Mol Pharm; 2018 Jan; 15(1):97-107. PubMed ID: 29164901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation.
    Chieng N; Aaltonen J; Saville D; Rades T
    Eur J Pharm Biopharm; 2009 Jan; 71(1):47-54. PubMed ID: 18644443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.